Chronic Spontaneous Urticaria (CSU) Overview
Learn About Chronic Spontaneous Urticaria (CSU)
Condition 101 content is not available at this time, but we are continually updating the site. Please check back.
However, there may be experts who have treated this or similar conditions in our Find a Doctor section and research may be available in our Latest Advances section.
Jonathan Bernstein is a Medical Genetics specialist and a Pediatrics provider in Palo Alto, California. Dr. Bernstein is rated as an Elite provider by MediFind in the treatment of Chronic Spontaneous Urticaria (CSU). His top areas of expertise are Hereditary Angioedema, Chronic Spontaneous Urticaria (CSU), Hypotonia, and Smith-Kingsmore Syndrome.
Office
Thomas Casale is an Internal Medicine provider in Omaha, Nebraska. Dr. Casale is rated as an Elite provider by MediFind in the treatment of Chronic Spontaneous Urticaria (CSU). His top areas of expertise are Asthma, Hives, Chronic Spontaneous Urticaria (CSU), and Allergic Rhinitis.
Ana Arnau-Gimenez practices in Barcelona, Spain. Ms. Arnau-Gimenez is rated as an Elite expert by MediFind in the treatment of Chronic Spontaneous Urticaria (CSU). Her top areas of expertise are Hives, Chronic Spontaneous Urticaria (CSU), Angioedema, and Contact Dermatitis.
Summary: TARGET-DERM is a longitudinal, observational study of adult and pediatric patients being managed for Atopic Dermatitis and other Immune-Mediated Inflammatory Skin Conditions (IMISC) in usual clinical practice. TARGET-DERM will create a research registry of patients with IMISC within academic and community real-world practices in order to assess the safety and effectiveness of current and future th...
Summary: The purpose of this extension study is to collect long-term efficacy and safety data on barzolvolimab in adult participants with Chronic Spontaneous Urticaria (CSU) who completed the treatment and follow-up periods of the Phase 3 clinical trials. This study will also fulfill the Celldex commitment to provide post-trial access to participants who have completed the phase 3 studies, where applicable...

